SG11202101922YA - Highly versatile method for granting new binding specificity to antibody - Google Patents

Highly versatile method for granting new binding specificity to antibody

Info

Publication number
SG11202101922YA
SG11202101922YA SG11202101922YA SG11202101922YA SG11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA
Authority
SG
Singapore
Prior art keywords
antibody
binding specificity
highly versatile
new binding
versatile method
Prior art date
Application number
SG11202101922YA
Other languages
English (en)
Inventor
Hiroaki Suga
Junichi Takagi
Original Assignee
Univ Tokyo
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo, Univ Osaka filed Critical Univ Tokyo
Publication of SG11202101922YA publication Critical patent/SG11202101922YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
SG11202101922YA 2018-07-31 2019-07-31 Highly versatile method for granting new binding specificity to antibody SG11202101922YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018144345 2018-07-31
PCT/JP2019/030081 WO2020027224A1 (ja) 2018-07-31 2019-07-31 新たな結合特異性を抗体に付与する超汎用法

Publications (1)

Publication Number Publication Date
SG11202101922YA true SG11202101922YA (en) 2021-03-30

Family

ID=69231246

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101922YA SG11202101922YA (en) 2018-07-31 2019-07-31 Highly versatile method for granting new binding specificity to antibody

Country Status (11)

Country Link
US (1) US20210317233A1 (ja)
EP (1) EP3831846A4 (ja)
JP (2) JP7303527B2 (ja)
KR (1) KR20210038580A (ja)
CN (1) CN112566928A (ja)
AU (1) AU2019313945A1 (ja)
CA (1) CA3111050A1 (ja)
EA (1) EA202190397A1 (ja)
IL (1) IL280500A (ja)
SG (1) SG11202101922YA (ja)
WO (1) WO2020027224A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230312651A1 (en) * 2020-07-10 2023-10-05 The University Of Tokyo Cyclic Peptide, Peptide Complex, and Drug Composition Containing Said Cyclic Peptide and/or Said Peptide Complex
WO2023179370A1 (en) * 2022-03-21 2023-09-28 The Hong Kong Polytechnic University Peptidic bispecific antibody, methods for preparation and uses thereof
WO2024048683A1 (ja) * 2022-08-30 2024-03-07 ミラバイオロジクス株式会社 人工タンパク質及び医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180343B1 (en) * 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
WO2001083525A2 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
EP1797127B1 (en) * 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
JP5605602B2 (ja) 2007-03-26 2014-10-15 国立大学法人 東京大学 環状ペプチド化合物の合成方法
EP2492344B1 (en) 2009-10-22 2016-04-06 PeptiDream Inc. Rapid display method in translational synthesis of peptide
US9657289B2 (en) 2010-12-03 2017-05-23 The University Of Tokyo Peptide with safer secondary structure, peptide library, and production methods for same
JP6138813B2 (ja) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体及びその使用
EP2862875B1 (en) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
US9890216B2 (en) * 2012-10-23 2018-02-13 Board Of Regents, The University Of Texas System Antibodies with engineered IgG Fc domains
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
JP6754997B2 (ja) 2013-08-26 2020-09-16 国立大学法人 東京大学 大環状ペプチド、その製造方法、及び大環状ペプチドライブラリを用いるスクリーニング方法
CN106589129B (zh) * 2016-12-30 2021-03-05 上海近岸生物科技有限公司 一种结合cd19、cd3和cd28的三功能分子及其应用
CN110997921A (zh) 2017-07-31 2020-04-10 国立大学法人东京大学 在蛋白质结构上呈递环肽的超通用方法

Also Published As

Publication number Publication date
JPWO2020027224A1 (ja) 2021-08-02
US20210317233A1 (en) 2021-10-14
EA202190397A1 (ru) 2021-06-11
EP3831846A1 (en) 2021-06-09
WO2020027224A1 (ja) 2020-02-06
AU2019313945A1 (en) 2021-03-18
CA3111050A1 (en) 2020-02-06
KR20210038580A (ko) 2021-04-07
JP2023093637A (ja) 2023-07-04
JP7303527B2 (ja) 2023-07-05
CN112566928A (zh) 2021-03-26
EP3831846A4 (en) 2022-05-11
IL280500A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
IL276537A (en) Antibodies bind to GPRC5D
ZA202203250B (en) Cd3 binding antibodies
ZA201808209B (en) Antibody for binding to interleukin 4 receptor
SG11202106214YA (en) Novel anti-ccr8 antibody
IL283939A (en) Antibodies bind to cd3
HK1252862A1 (zh) 結合cd45的抗體分子
IL287613A (en) Antibodies that bind gprc5d
IL274370A (en) Single-region antibodies that bind CD137
IL256870B (en) Constructs for bispecific antibodies that bind to CD70 and CD3 and uses thereof
EP3294766C0 (en) HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3
HK1250737A1 (zh) 結合cd79的抗體分子
SG11201709908QA (en) Method for quantifying monoclonal antibody
IL292727A (en) Multispecific antibodies
IL282590A (en) Heavy chain antibodies that bind to CD38
ZA201907065B (en) Monoclonal antibody to pd-l1
IL280500A (en) A super versatile method to deliver a novel binder with tailored specificity to an antibody
SG11201800326YA (en) Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor
GB201811403D0 (en) Antibody molecules
EP3458077A4 (en) METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
IL269394A (en) Antibodies bind to STEAP-1
IL292698A (en) Amino-terminated scfv multispecific binding molecules
IL292799A (en) Antibodies against siglec-9
IL289959A (en) Antibody purification methods
IL277056A (en) Methods for purifying antibodies
GB201709379D0 (en) Humanised ADAMTS13 binding antibodies